Leap therapeutics announces first patient enrolled in defiance study of dkn-01 for the treatment of colorectal cancer patients

Cambridge, mass. , oct. 17, 2022 /prnewswire/ -- leap therapeutics, inc. (nasdaq: lptx), a biotechnology company focused  on developing targeted and immuno-oncology therapeutics, today announced that the first patient has been enrolled in the phase 2 defiance study evaluating dkn-01, leap's anti-dickkopf-1 antibody (dkk1), in combination with standard of care bevacizumab and chemotherapy as a second-line treatment for patients with advanced colorectal cancer (crc).
LPTX Ratings Summary
LPTX Quant Ranking